Sirtuins as endogenous regulators of lung fibrosis: A current perspective

Life Sciences ◽  
2020 ◽  
Vol 258 ◽  
pp. 118201
Author(s):  
Somnath Mazumder ◽  
Mukta Barman ◽  
Uday Bandyopadhyay ◽  
Samik Bindu
Keyword(s):  
Lung Fibrosis ◽  
Current Perspective ◽  
Endogenous Regulators ◽  
A Current

scholarly journals Progressive Fibrosing Interstitial Lung Diseases: A Current Perspective

Biomedicines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 1237
Author(s):  
Carlo Albera ◽  
Giulia Verri ◽  
Federico Sciarrone ◽  
Elena Sitia ◽  
Mauro Mangiapia ◽  
...  
Keyword(s):  
Lung Fibrosis ◽  
Lung Diseases ◽  
Current Knowledge ◽  
Relevant Literature ◽  
Interstitial Lung Diseases ◽  
Current Perspective ◽  
Similar Disease ◽  
Diagnostic Approaches ◽  
Disease Behavior ◽  
A Current

Interstitial lung diseases (ILDs) are a large and diverse group of rare and chronic respiratory disorders, with idiopathic pulmonary fibrosis (IPF) being the most common and best-studied member. Increasing interest in fibrosis as a therapeutic target and the appreciation that fibrotic mechanisms may be a treatable target of IPF prompted the development and subsequent approval of the antifibrotics, pirfenidone and nintedanib. The management of ILDs has changed considerably following an understanding that IPF and some ILDs share similar disease behavior of progressive fibrosis, termed “progressive fibrosing phenotype”. Indeed, antifibrotic treatment has shown to be beneficial in ILDs characterized by the progressive fibrosing phenotype. This narrative review summarizes current knowledge in the field of progressive fibrosing ILDs. Here, we discuss the clinical characteristics and pathogenesis of lung fibrosis and highlight relevant literature concerning the mechanisms underlying progressive fibrosing ILDs. We also summarize current diagnostic approaches and the available treatments of progressive fibrosing ILDs and address the optimization of treating progressive fibrosing ILDs with antifibrotics in clinical practice.

scholarly journals Cell-free riboswitches

2021 ◽  
Author(s):  
Takeshi Tabuchi ◽  
Yohei Yokobayashi
Keyword(s):  
Protein Synthesis ◽  
The State ◽  
Future Directions ◽  
Free Protein ◽  
Current Perspective ◽  
Gene Switches ◽  
A Current ◽  
Cell Free Protein Synthesis

Synthetic riboswitches can be used as chemical gene switches in cell-free protein synthesis systems. We provide a current perspective on the state of cell-free riboswitch technologies and their future directions.

scholarly journals Heparin-induced thrombocytopenia: research and clinical updates

Hematology ◽  
2016 ◽  
Vol 2016 (1) ◽  
pp. 262-268 ◽  
Author(s):  
Oluwatoyosi Onwuemene ◽  
Gowthami M. Arepally
Keyword(s):  
Limited Data ◽  
Platelet Factor ◽  
Heparin Induced Thrombocytopenia ◽  
Diagnostic Strategies ◽  
Immune Mediated ◽  
Emerging Therapies ◽  
Current Perspective ◽  
Clinical Advances ◽  
A Current

Abstract Heparin-induced thrombocytopenia (HIT) remains an important diagnosis to consider in hospitalized patients developing thrombocytopenia. HIT is an immune-mediated prothrombotic disorder caused by antibodies to platelet factor 4 (PF4) and heparin. Recent basic scientific studies have advanced our understanding of disease pathogenesis through studies of the PF4/heparin structure, immune mechanisms, and cellular basis of thrombosis. Clinical advances have also occurred in areas of HIT prevention, description of disease variants, and diagnostic strategies. Emerging anticoagulants with the potential to change HIT treatment are evolving, although with limited data. This review will provide a current perspective on HIT pathogenesis, disease features, diagnostic strategies, and role of emerging therapies for the management of HIT.

Sign in / Sign up

Export Citation Format

Share Document